Enhanced Postsurgical Cancer Treatment Using Methacrylated Glycol Chitosan Hydrogel for Sustained DNA/Doxorubicin Delivery and Immunotherapy
Copyright © 2024 Hee Seung Seo et al..
Background: Cancer recurrence and metastasis are major contributors to treatment failure following tumor resection surgery. We developed a novel implantable drug delivery system utilizing glycol chitosan to address these issues. Glycol chitosan is a natural adjuvant, inducing dendritic cell activation to promote T helper 1 cell immune responses, macrophage activation, and cytokine production. Effective antigen production by dendritic cells initiates T-cell-mediated immune responses, aiding tumor growth control. Methods: In this study, we fabricated multifunctional methacrylated glycol chitosan (MGC) hydrogels with extended release of DNA/doxorubicin (DOX) complex for cancer immunotherapy. We constructed the resection model of breast cancer to verify the anticancer effects of MGC hydrogel with DNA/DOX complex. Results: This study demonstrated the potential of MGC hydrogel with extended release of DNA/DOX complex for local and efficient cancer therapy. The MGC hydrogel was implanted directly into the surgical site after tumor resection, activating tumor-related immune cells both locally and over a prolonged period of time through immune-reactive molecules. Conclusions: The MGC hydrogel effectively suppressed tumor recurrence and metastasis while enhancing immunotherapeutic efficacy and minimizing side effects. This biomaterial-based drug delivery system, combined with cancer immunotherapy, can substantial improve treatment outcomes and patient prognosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Biomaterials research - 28(2024) vom: 19., Seite 0008 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Seo, Hee Seung [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 28.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.34133/bmr.0008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370224523 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370224523 | ||
| 003 | DE-627 | ||
| 005 | 20240329001157.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240328s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.34133/bmr.0008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1353.xml |
| 035 | |a (DE-627)NLM370224523 | ||
| 035 | |a (NLM)38532906 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Seo, Hee Seung |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Enhanced Postsurgical Cancer Treatment Using Methacrylated Glycol Chitosan Hydrogel for Sustained DNA/Doxorubicin Delivery and Immunotherapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2024 Hee Seung Seo et al. | ||
| 520 | |a Background: Cancer recurrence and metastasis are major contributors to treatment failure following tumor resection surgery. We developed a novel implantable drug delivery system utilizing glycol chitosan to address these issues. Glycol chitosan is a natural adjuvant, inducing dendritic cell activation to promote T helper 1 cell immune responses, macrophage activation, and cytokine production. Effective antigen production by dendritic cells initiates T-cell-mediated immune responses, aiding tumor growth control. Methods: In this study, we fabricated multifunctional methacrylated glycol chitosan (MGC) hydrogels with extended release of DNA/doxorubicin (DOX) complex for cancer immunotherapy. We constructed the resection model of breast cancer to verify the anticancer effects of MGC hydrogel with DNA/DOX complex. Results: This study demonstrated the potential of MGC hydrogel with extended release of DNA/DOX complex for local and efficient cancer therapy. The MGC hydrogel was implanted directly into the surgical site after tumor resection, activating tumor-related immune cells both locally and over a prolonged period of time through immune-reactive molecules. Conclusions: The MGC hydrogel effectively suppressed tumor recurrence and metastasis while enhancing immunotherapeutic efficacy and minimizing side effects. This biomaterial-based drug delivery system, combined with cancer immunotherapy, can substantial improve treatment outcomes and patient prognosis | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Han, Jun-Hyeok |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Jaesung |e verfasserin |4 aut | |
| 700 | 1 | |a Bae, Ga-Hyun |e verfasserin |4 aut | |
| 700 | 1 | |a Byun, Min Ji |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Chi-Pin James |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Jieun |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Juwon |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Hee Ho |e verfasserin |4 aut | |
| 700 | 1 | |a Shin, Mikyung |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Tae-Eun |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Tae-Hyung |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Se-Na |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Wooram |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Chun Gwon |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomaterials research |d 2014 |g 28(2024) vom: 19., Seite 0008 |w (DE-627)NLM251684407 |x 1226-4601 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2024 |g day:19 |g pages:0008 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.34133/bmr.0008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2024 |b 19 |h 0008 | ||